Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238538 | 1.00 | MIF (0.35) | MIF | |
| SCHEMBL9365286 | 1.00 | MIF (0.35) | MIF | |
| SCHEMBL916725 | 1.00 | MIF (0.35) | MIF | |
| Pivalate SCHEMBL7524185 | 0.95 | MIF (0.33) | MIF | |
| SCHEMBL18737178 | 0.89 | MIF (0.32) | MIF | |
| SCHEMBL21637552 | 0.89 | MIF (0.32) | MIF | |
| SCHEMBL13290686 | 0.89 | MIF (0.32) | MIF | |
| SCHEMBL12593871 | 0.89 | MIF (0.32) | MIF | |
| SCHEMBL4188806 | 0.89 | MIF (0.34) | MIF | |
| SCHEMBL12648308 | 0.89 | MIF (0.34) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007096751-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN CALCIUM | CADILA HEALTHCARE LIMITED (IN) | 2007-08-30 | — | — | WO | claimed |
| CN-118063326-A | Method for promoting nickel catalysis to synthesize arylamine compound by red light | 陕西师范大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-116655514-A | Preparation and application of isotope-labeled atorvastatin photoaffinity probe | 中国医学科学院药物研究所 | 2023-08-29 | — | — | CN | disclosed |
| CN-109503542-B | Atorvastatin calcium intermediate and preparation method and application thereof | 浙江宏元药业股份有限公司 | 2020-08-18 | — | — | CN | disclosed |
| WO-2020016903-A1 | AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS. | ARCH PHARMALABS LIMITED (IN) | 2020-01-23 | — | — | WO | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-2679580-B1 | THIOAMIDE COMPOUND, METHOD FOR PRODUCING THIOAMIDE COMPOUND, METHOD FOR PRODUCING [(4R,6R)-6-AMINOETHYL-1,3-DIOXAN-4-YL]ACETATE DERIVATIVE, AND METHOD FOR PRODUCING ATORVASTATIN | MICROBIAL CHEM RES FOUND (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017060885-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2017-04-13 | — | — | WO | disclosed |
| CN-105503815-A | Preparation method of synthetic intermediate of Lipitor | UNIV LANZHOU | 2016-04-20 | — | — | CN | disclosed |
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| WO-2005053614-A2 | ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6777552-B2 | FROM AN ESTER DERIVATIVE OR PROTECTED ESTER DERIVATIVE OF THE STATIN BY USING CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-06-19 | — | — | US | disclosed |
| EP-1054860-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIOLS | Warner-Lambert Export Limited (IE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999032434-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIOLS | WARNER-LAMBERT EXPORT LIMITED (IE) | 1999-07-01 | — | — | WO | disclosed |
| EP-0330172-B1 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER LAMBERT CO (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0553213-A1 | PROCESS FOR THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL-6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE. | WARNER LAMBERT CO (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5155251-A | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate | WARNER-LAMBERT COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| WO-1992006968-A1 | PROCESS FOR THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL-6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE | WARNER-LAMBERT COMPANY (US) | 1992-04-30 | — | — | WO | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | MIF 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.